Antigenicity of borrelial protein BBK32 fragments in early Lyme borreliosis

Lahdenne, Pekka; Sarvas, Heikki; Kajanus, Riikka; Eholuoto, Miia; Sillanpää, Heidi; Seppälä, Ilkka

doi:10.1099/jmm.0.46621-0

Cited by 5 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, studies with BBK32 indicate that protein fragments may be better suited for early Lyme disease serology. We are currently investigating that approach for RevA, using various protein fragments to eliminate possible cross-reactive epitopes and increase the specificity of this serological test (23).…”

Section: Discussionmentioning

confidence: 99%

The Borrelial Fibronectin-Binding Protein RevA Is an Early Antigen of Human Lyme Disease

Brissette

Rossmann²,

Bowman

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

Previous studies using small numbers of serum samples from human patients and experimentally infected animals identified the frequent presence of antibodies recognizing RevA, a borrelial fibronectinbinding outer surface protein. We now demonstrate that most examined Lyme disease spirochetes from North America and Europe contain genes encoding RevA proteins, some with extensive regions of conservation and others with moderate diversity. Line blot analyses using recombinant RevA from two diverse Lyme disease spirochetes of RevA and serum samples from culture-confirmed human Lyme disease patients from the United States (n ‫؍‬ 46, mainly with early Lyme disease) and Germany (>500, with early and late manifestations of Lyme disease) were performed. The results indicated that a sizable proportion of patients produced antibodies that recognized recombinant RevA. Overall, RevA-based serological studies were less sensitive and less specific than other assay types, such as the VlsE-based C6 peptide assay. However, sera from patients in the initial stages of Lyme disease contained antibodies against RevA, demonstrating that this protein is expressed early in human infection. Thus, RevA may be a useful target for preventative or curative therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

The Borrelial Fibronectin-Binding Protein RevA Is an Early Antigen of Human Lyme Disease

Brissette

Rossmann²,

Bowman

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…qRT-PCR analyses revealed that bbk32 was expressed at substantially lower levels in the DMC-cultivated wild-type Bb (0.005 copies per 100 flaB) used for the microarray hybridizations compared with their in vitro counterparts (20.79 copies per 100 flaB). These data, however, seemed to be at odds with the demonstrated expression of BBK32 during infection (Lahdenne et al, 2006;Li et al, 2006) and its potential role in virulence , prompting us to examine RNAs from additional DMC-cultivated c162 (wild type) and c174 (rpoS mutant). Results from these subsequent analyses yielded substantially higher bbk32 transcript levels (11.13 copies per 100 flaB) in the wild-type isolate and demonstrated a level of RpoS dependence (46.5-fold, P < 0.01) comparable to that observed at 37°C in vitro (data not shown).…”

Section: The In Vitro Rpos Regulon Differs Substantially From Its Dmcmentioning

confidence: 99%

Analysis of the RpoS regulon in Borrelia burgdorferi in response to mammalian host signals provides insight into RpoS function during the enzootic cycle

Caimano¹,

Iyer

Eggers³

et al. 2007

Molecular Microbiology

235

501

View full text Add to dashboard Cite

show abstract

“…Fibronectin-binding protein BBK32 plays an important role in the attachment to the extracellular matrix. BBK32 is highly immunogenic and is present in sera of Lyme disease-infected patients (Heikkilä et al 2002;Lahdenne et al 2006). BBK32 antisera can interfere with borrelial transmission at various stages of the vector-host life cycle (Fikrig et al 2000).…”

Section: Prophylactic Treatment Strategiesmentioning

confidence: 99%

Novel targets and strategies to combat borreliosis

Strnad

Grubhoffer

Rego

2020

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Lyme borreliosis is a bacterial infection that can be spread to humans by infected ticks and may severely affect many organs and tissues. Nearly four decades have elapsed since the discovery of the disease agent called Borrelia burgdorferi. Although there is a plethora of knowledge on the infectious agent and thousands of scientific publications, an effective way on how to combat and prevent Lyme borreliosis has not been found yet. There is no vaccine for humans available, and only one active vaccine program in clinical development is currently running. A spirited search for possible disease interventions is of high public interest as surveillance data indicates that the number of cases of Lyme borreliosis is steadily increasing in Europe and North America. This review provides a condensed digest of the history of vaccine development up to new promising vaccine candidates and strategies that are targeted against Lyme borreliosis, including elements of the tick vector, the reservoir hosts, and the Borrelia pathogen itself.

show abstract

Antigenicity of borrelial protein BBK32 fragments in early Lyme borreliosis

Cited by 5 publications

References 23 publications

The Borrelial Fibronectin-Binding Protein RevA Is an Early Antigen of Human Lyme Disease

The Borrelial Fibronectin-Binding Protein RevA Is an Early Antigen of Human Lyme Disease

Analysis of the RpoS regulon in Borrelia burgdorferi in response to mammalian host signals provides insight into RpoS function during the enzootic cycle

Novel targets and strategies to combat borreliosis

Contact Info

Product

Resources

About